CBO Stock Overview A clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. More details
Risk Analysis + 3 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Imunon Historical stock prices Current Share Price US$0.78 52 Week High US$3.70 52 Week Low US$0.44 Beta 2.09 1 Month Change 18.18% 3 Month Change -13.81% 1 Year Change 16.42% 3 Year Change -90.37% 5 Year Change -96.36% Change since IPO -99.93%
Recent News & Updates
IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer Dec 20
Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001 Dec 11
Imunon, Inc. Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2) Nov 28
Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer Nov 26
New major risk - Financial position Nov 09
IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001 Nov 08 See more updates
IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer Dec 20
Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001 Dec 11
Imunon, Inc. Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2) Nov 28
Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer Nov 26
New major risk - Financial position Nov 09
IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001 Nov 08
Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting Oct 30
Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary Oct 07 Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million. Sep 04
Imunon, Inc. announced that it has received $10 million in funding Aug 16
New major risk - Shareholder dilution Aug 03 Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Aug 01
Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Jun 24
IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial Jun 06
IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study May 15 IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024
Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024 May 08
Imunon, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101 Apr 20 Imunon, Inc. has withdrawn its Follow-on Equity Offering. Apr 11
New major risk - Financial position Mar 29 Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024
New major risk - Share price stability Jan 25
Imunon Receives Non-Compliance Notice From Nasdaq Dec 30 Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Dec 21
Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer Dec 12
Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer Dec 11
New major risk - Share price stability Dec 05
Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022) Nov 16
Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer Nov 15
IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer Oct 19
Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board Oct 07
Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board Aug 15
First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022) Aug 14
New major risk - Financial position Aug 11
IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv Aug 09
New major risk - Share price stability Jul 04 Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors Jun 16
First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022) May 14
Full year 2022 earnings released: US$5.03 loss per share (vs US$3.83 loss in FY 2021) Mar 31
Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023 Feb 12 Imunon Appoints Corinne Le Goff as Chief Executive Officer
Imunon, Inc. Announces Board Changes Jan 04
Third quarter 2022 earnings released: US$0.87 loss per share (vs US$0.94 loss in 3Q 2021) Nov 16 Imunon Appoints James E. Dentzer to Its Board of Directors
Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer Sep 16
Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology Sep 02
First half 2022 earnings released: US$2.86 loss per share (vs US$4.26 loss in 1H 2021) Aug 16
Insufficient new directors Jul 21 Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director
Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Jun 22
First quarter 2022 earnings released: US$1.82 loss per share (vs US$1.29 loss in 1Q 2021) May 18
Celsion Corporation, Annual General Meeting, Jun 13, 2022 May 02
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress Apr 22
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting Apr 16 Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million. Apr 11
Full year 2021 earnings released: US$3.83 loss per share (vs US$10.08 loss in FY 2020) Apr 01
Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021 Apr 01
Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Feb 18
Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate Feb 01
Celsion Corporation announced that it expects to receive $28.5 million in funding Jan 12
Third quarter 2021 earnings released: US$0.063 loss per share (vs US$0.24 loss in 3Q 2020) Nov 16
Celsion Corporation Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform Sep 03
First half 2021 earnings released: US$0.15 loss per share (vs US$0.37 loss in 1H 2020) Aug 18
Celsion Corporation Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer Jul 20
Celsion Corporation Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer Jul 02
Celsion Corporation(NasdaqCM:CLSN) dropped from Russell Microcap Growth Index Jun 28
First quarter 2021 earnings released: US$0.086 loss per share (vs US$0.20 loss in 1Q 2020) May 15
Full year 2020 earnings released: US$0.67 loss per share (vs US$0.77 loss in FY 2019) Mar 20
Celsion Corporation Announces Update on Phase I/II Ovation 2 Study Mar 04
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores Feb 26
Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (Nol) Program Feb 24
Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer Feb 23
Celsion Corporation Announces Formation of Vaccine Advisory Board Feb 13
New 90-day high: €1.82 Feb 09
Celsion Corporation Files Provisional U.S. Patent Application for A Broad Range of Next Generation DNA Vaccines Jan 29
Celsion Corporation has completed a Follow-on Equity Offering in the amount of $34.999999 million. Jan 28
New 90-day high: €0.78 Jan 11
Celsion Corporation Announces the Retirement of Dr. Alberto Martinez from the Board of Directors Jan 01
Rosen Law Firm Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action Dec 25
New 90-day high: €0.69 Dec 11 Shareholder Returns CBO DE Biotechs DE Market 7D -0.6% -2.6% -2.0% 1Y 16.4% -13.2% 6.8%
See full shareholder returns
Return vs Market: CBO exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is CBO's price volatile compared to industry and market? CBO volatility CBO Average Weekly Movement 9.8% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CBO's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CBO's weekly volatility has decreased from 35% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 1982 33 Stacy Lindborg imunon.com
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
Show more Imunon, Inc. Fundamentals Summary How do Imunon's earnings and revenue compare to its market cap? CBO fundamental statistics Market cap €11.56m Earnings (TTM ) -€18.69m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CBO income statement (TTM ) Revenue US$0 Cost of Revenue US$1.67m Gross Profit -US$1.67m Other Expenses US$17.78m Earnings -US$19.45m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 01:51 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Imunon, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Raymond Deacon Brean Capital Kumaraguru Raja Brookline Capital Markets
Show 14 more analysts 
